The shortage of popular diabetes and weight-loss drugs known as GLP-1s — and insurers’ uneven coverage of them — is putting an unprecedented supply of compounded drugs in consumers' medicine cabinets.

Hims & Hers Health Inc is a multi-specialty telehealth platform that connects consumers to licensed healthcare professionals, ...

Online companies like Noom and Hims & Hers this year began selling compounded semaglutide, the active ingredient in Ozempic ...

Hims & Hers Health (HIMS) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.

Hims & Hers stock is currently in the middle of a deep drawdown. Read why I maintain my strong buy rating on HIMS stock.

After starting it in February, I noticed regrowth around the temples by June and thicker, stronger hair overall by August.” ...

While this class of drugs becomes ever more prevalent, and the wide-ranging positive health outcomes become better known, ...

Hims & Hers is a fantastic value despite its high on-the-surface P/E ratio and valuation metrics. Click here to read why HIMS ...

As of 16 September at 11:41 GMT-4. Market open. Adjusted closing price adjusted for splits and dividend and/or capital gain distributions.

The city government here is hopeful that more students will be encouraged to embrace science and technology courses as an ...

The Dutch Research Council NWO has announced the launch of HyPRO, the largest R&D project into green hydrogen in the Netherlands to date. With a total budget of over €50 million it aims to boost ...